gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · GUTSHealthcareSurgical Instruments

Fractyl Health, Inc. Common Stock (GUTS)

$0.9725+8.27%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$0.97▼ 92.76% in range
Nov 4, 2025Low $0.88 · High $58.55Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Fractyl Health closed at $0.97 on Nov 4, up 8.27%, 98.3% below its 52-week closing high. Volume of 166.1K shares was 0.14× its 20-day average (below normal).

Split-adjusted performance: -78.7% over one month, -89.0% over six months, -93.2% over one year.

Short interest was 265.3K shares at the Oct 15 settlement, down 87.7% from the prior report (2.7% of float, 1.2 days to cover).

Market cap$12.9M13.3M shares
Revenue · quarter$0.00—
Diluted EPS$-1.92—
P/E · TTM—
Net margin—
Dividend yieldNone
52-week range0.88 – 58.55−98.3% from high
Volume166.1K0.14× 20-day avg
Volatility · 60d748.9%Annualised
Short % of float2.7%1.2 days to cover
Net cash$16.7MCash $47.1M
Next earnings—Not scheduled
Split-adjusted performance
1W +9.3%1M −78.7%3M −88.2%6M −89.0%YTD −96.3%1Y −93.2%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum3
Revenue growth—
Net margin—
Value (low P/E)—
Size18

Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.

Short interest

Details →
Shares short265.3K−87.7% vs prior
Days to cover1.2Settled Oct 15
% of float2.7%
Short vol. 10d53.3%of daily volume

Closest peers by size in Surgical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
GUTSFractyl Health$0.9725+8.27%−89.0%———$12.9M
SINTSiNtx Technologies$1.66−3.49%−30.8%+199.3%−803.5%—$12.5MCompare
PAVMPAVmed$1.66−8.79%−76.3%+450.0%−16603.0%—$13.3MCompare
FEMYFemasys$1.44+2.86%−84.1%−18.9%−1346.8%—$12.1MCompare
CTSOCytosorbents$4.56+0.44%−60.0%+0.2%−45.9%—$14.4MCompare
ICUSeaStar Medical Holding$2.04+2.00%−58.1%+82.0%−606.5%—$10.8MCompare
MODDModular Medical$1.67−5.65%−57.3%———$15.9MCompare
PMIPicard Medical$7.19−7.58%−38.0%—−191.6%—$16.8MCompare
RVPRetractable Technologies$0.5660+0.71%−18.3%−31.1%38.5%—$16.9MCompare

News about Fractyl Health

All news →
Pomerantz Law Firm Announces the Filing of a Class Action Against Fractyl Health, Inc. and Certain Officers – GUTSGlobeNewswire Inc. · Oct 20, 2026▼ NegativeGUTS DEADLINE TUESDAY: Bragar Eagel & Squire, P.C. Urges Fractyl Health, Inc. Stockholders with Large Losses to Contact the Firm Before October 20thGlobeNewswire Inc. · Oct 19, 2026▼ NegativeBronstein, Gewirtz & Grossman LLC Urges Fractyl Health, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc. · Oct 15, 2026▼ NegativeBragar Eagel & Squire, P.C. Urges Fractyl Health, Inc. Stockholders with Large Losses to Contact the Firm Before October 20thGlobeNewswire Inc. · Oct 1, 2026▼ NegativeDEADLINE ALERT for FTK, AVEX, GUTS, GDDY: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class ActionsGlobeNewswire Inc. · Sep 24, 2026▼ Negative

Quick answers

What does Fractyl Health do?
Fractyl Health Inc is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D). Its Revita and Rejuva candidates are designed to target root causes of metabolic diseases, allowing the company to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease.
What is GUTS's market cap?
$12.90M, based on the Nov 4 close of $0.97.
Does Fractyl Health pay a dividend?
No regular cash dividend has been paid in the last year.
How much of GUTS is sold short?
265.3K shares, 2.7% of float, as of Oct 15, 2026.
What sector is GUTS in?
Healthcare, in the Surgical Instruments industry.

About Fractyl Health

Fractyl Health Inc is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D). Its Revita and Rejuva candidates are designed to target root causes of metabolic diseases, allowing the company to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease. The Revita DMR System (Revita), its lead product candidate, is based on its insights surrounding the potential role of the gut in obesity.

HQ: Burlington, MA73 employeesListed Feb 2, 2024fractyl.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology